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Abstract
Angiogenesis is a critical factor in the growth and dissemination of solid tumors. Indeed, tumor vasculature is abnormal and
contributes to the development and spread of malignancies by creating a hostile microenvironment. The alternative SDF-1/
CXCL12 receptor, CXCR7, is frequently and specifically expressed in tumor-associated vessels. In this study, we examine the
role of endothelium-expressed CXCR7 in tumor vascular dysfunction by specifically examining the contribution of CXCR7 to
endothelial cell (EC) proliferation. We demonstrate that CXCR7 expression is sufficient to drive post-confluent growth in EC
cultures. Further, we provide a novel mechanism for CXCR7-mediated proliferation via proteasomal degradation of the
tumor suppressor protein Rb. These findings identify a heretofore unappreciated role for CXCR7 in vascular dysfunction and
confirm this receptor as a plausible target for anti-tumor therapy.
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Introduction
Angiogenesis is the process by which new vessels form from
existing vascular networks in both the blood and lymphatic
circulatory systems. This highly regulated process is critical for
wound healing and tissue regeneration but is co-opted in a variety
of pathogenic processes including angioproliferative diseases and
the growth of aberrant vasculature into tumors [1]. Endothelial
cells (EC) line all vessels and are key players in the angiogenic
process. In normal vessels, EC are long-lived, quiescent cells that
are highly dependent upon cell-cell and cell-substrate adhesion for
their survival and function. Angiogenesis requires both EC
migration into an angiogenic niche and EC proliferation in order
to form new vascular structures [2].
The vasculature that forms in the tumor microenvironment is
structurally and functionally abnormal compared to vessels formed
during normal wound healing. This vascular dysfunction is a direct
result of abnormalities in EC function and vessels formed by this
pathological process do not allow correct circulation within the
tumor tissue. The result is a hostile tumor microenvironment
characterized by abnormally high interstitial pressure, low pH,
poor oxygenation and poor immune surveillance. Tumor vascular
dysfunction exacerbates the development and spread of cancer by
selecting for tumor cells that can survive and proliferate under
these adverse conditions, thereby enhancing malignancy and
driving the development of metastases [3].
Chemokines and their receptors are important players in
pathological angiogenesis [4] as well as the migration and invasion
of tumor cells [5,6]. The chemokine SDF-1/CXCL12 and its
canonical receptor CXCR4 are among the most highly studied
chemokine/receptor pairs in cancer biology [7,8]. A second
receptor for SDF-1/CXCL12 was recently discovered and
designated CXCR7 [9]. Since its discovery as an alternative
receptor for SDF-1/CXCL12, a number of studies have explored
the expression of CXCR7 in tumors. CXCR7 is sporadically
expressed by tumor cells in renal [10], breast [11,12], lung [12],
liver [13], prostate [14] and central nervous system [15] cancers
and the implications of CXCR7 expression for malignant
progression are currently an area of intense investigation. EC
express very low levels of CXCR7 under normal physiological
conditions in vivo [12] and normal culture conditions in vitro [9],
but CXCR7 is induced in activated EC [9] suggesting that
CXCR7 may participate in the response of EC to physiological
stress. Interestingly, several studies have shown that tumor-
associated EC display aberrant CXCR7 expression in a variety
of cancer models [11,16,17]. Indeed, one such study by Miao et.
al. demonstrated profound and highly specific expression of
CXCR7 in vessels associated with malignancies of the breast, lung,
liver, ovary, kidney and bladder, leading the authors to postulate
that CXCR7 might be a specific marker of tumor endothelium
[12]. Despite the fact that CXCR7 expression is extensively and
specifically observed on tumor-associated vasculature in both
primary tumors and metastases, the functional consequences of
CXCR7 expression in EC remain poorly understood.
Although CXCR7 expression has been linked to cellular
proliferation both in cancer models [9,12,13,17,18], and EC
cultures [19], the current literature fails to establish the
mechanisms by which CXCR7 influences cell division. In this
study, we investigate CXCR7-mediated proliferation in adult
primary lymphatic EC. We demonstrate that CXCR7+ EC
cultures display post-confluent proliferation, the extent of which
corresponds to their level of CXCR7 expression. We discover via a
protein microarray screen that CXCR7 influences the expression
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of multiple proteins involved in cell cycle control, including the
tumor suppressor protein retinoblastoma (Rb). We verify that that
CXCR7+ EC cultures have reduced levels of Rb and that Rb
expression can be rescued by inhibiting the proteasome. We use
ligand neutralization, pharmacological receptor targeting and
receptor mutagenesis to establish that the loss of Rb in CXCR7+
EC requires CXCR7 ligands and that rescue of Rb expression is
associated with decreased proliferation. These results identify
CXCR7 as a mediator of aberrant proliferation in EC and
establish CXCR7 as a potential therapeutic target for pathological
angioproliferation in cancer.
Materials and Methods
Cell Lines and Reagents
Primary Human Adult Lymphatic and Blood Vascular Endo-
thelial Cells (pLEC and pBEC, respectively) were commercially
obtained (Lonza) and maintained in EGM-2 medium (Lonza
#CC-3024) containing bullet kit growth supplements (Lonza
#CC-3124), 10% fetal bovine serum (FBS, Hyclone SH30396.03)
and Penicillin/Streptomycin/L-Glutamine (PSG, Hyclone
SV30082.01). All primary EC cultures were used between passage
4 and 10. MouseIgG1-anti-CXCR7 antibody (11G8) was provided
by Chemocentryx, Inc (Mountain View, CA), MouseIgG2b-anti-
CXCR7 antibody (clone 8F11, 331102), AlexaFluor647-conjugat-
ed mouseIgG1-anti-CXCR3 antibody (334903) and Mouse-IgG1
isotype control (401402) were from Biolegend. Mouse-IgG2b
(556654) and Pacific Blue Mouse–IgG2a (558118) isotype controls
were from BD Pharmingen. MouseIgG2a-anti-CD31/PECAM
antibody for IFA was from Thermo/Fisher (MA3100). Rabbit-
anti-HA (sc-805), Rabbit-IgG Isotype control (sc-2027) and HRP-
conjugated anti-mouse (sc-2306) anti-rabbit (sc-2305) were from
Santa Cruz Biotechnology. Rb antibody was from Cell Signaling
(9309) and GAPDH antibody was from Abcam (ab8245). Anti-
mouseIgG2a-AlexaFluor488 (A21131), anti-mouseIgG1-Alexa-
Fluor594 (A21125), anti-rabbit-AlexaFluor488 (A110088) and
Streptavidin-Pacific Blue (S11222) were from Invitrogen. HA-
HRP direct conjugate was from Roche (12013819011). Recom-
binant human SDF-1/CXCL12 (350-NS-050) and neutralizing
antibodies against SDF-1/CXCL12 (AF-310-NA) and ITAC/
CXCL11 (AF260) and biotinylated MouseIgG2a-anti-CXCR4
antibody (clone 12G5, FAB170B) were from R&D Systems. The
CXCR7 small molecule antagonist CCX733 was a generous gift
from Chemocentryx, Inc. Propidium Iodide was from Sigma
(P4170).
CXCR7 Adenovirus Vectors
CXCR7-expressing vectors with an N-terminal HA tag were
constructed by subcloning the DNA fragment into pAdTet7. This
vector contains the tet-responsive enhancer within a minimal
CMV promoter followed by the SV40 late poly(A) cassette,
adenovirus E1A, and a single loxP site to increase recombination
frequency. Recombinant adenoviruses were produced by co-
transfection of 293 cells expressing the Cre recombinase with
adenovirus DNA (Ad5-y5) that contains an E1A/E3-deleted
adenovirus genome and pAdtet7-HA-CXCR7 or pAdtet7-HA-
CXCR7-D5. Recombinant adenoviruses were expanded on 293-
Cre cells, and the bulk stocks were titered on 293 cells by limiting
dilution. Expression was driven by co-infection with Ad-Trans
expressing the Tet-off transactivator.
Infection of EC with Adenovirus Vectors
Adenovirus infections were performed on confluent EC cultures
in endothelial SFM medium (endoSFM, Gibco 11111) supple-
mented with 1% FBS, PSG and 37.5 mg/ml endothelial cell
growth supplement (ECGS, BD Biosystems 356006). Where
appropriate, infection medium was replaced with medium
containing drugs or neutralizing antibodies at 6 hours post-
infection.
Indirect Immunofluorescence and Image Analysis - EC were plated on
collagen-coated coverslips (BD Biosystems 354089) and infected
with either Trans at MOI 100 only or Trans at MOI 100 and
CXCR7 at MOI 100. At 20 hours post-infection, cells were
washed once with phosphate buffered saline containing calcium
and magnesium (PBS+) and fixed in PBS+ containing 2%
paraformaldehyde (PFA). Coverslips were blocked for 15 min at
room temperature (RT) in PBS+0.2% saponin+2% normal goat
serum (NGS). All further incubations were performed in
PBS+0.2% saponin+0.2% NGS. Primary antibodies were diluted
1:200 and applied for 30 minutes at RT. Secondary antibodies
and 49,6-diamidino-2-phenylindole (DAPI) were diluted 1:1000
and applied for 30 minutes at RT. Coverslips were washed and
mounted on glass slides with FluoromountG (Southern Biotech,
0100-01). For the barrier formation studies, cultures were
trypsinized at 20 hours post-infection, counted and 2(10)5 cells
were replated in duplicate into 8-well Permanox chamber slides
(NUNC 1177445) coated with 1% gelatin, allowed to form a new
monolayer for a further 20 hours then fixed in PBS+ containing
2% PFA and 1% TritonX-100 for 15 minutes at RT. Coverslips
were then post-fixed for a further 5 minutes at RT in PBS+
containing 2% PFA only. Coverslips were blocked in PBS+ with
1% TritonX-100 and 2% NGS for 15 minutes at RT. All further
incubations were performed in PBS+ with 1% TritonX-100 and
0.2% NGS (Tx Wash). Antibody concentrations were the same as
above. Image acquisition was on a Deltavision real-time
deconvolution (DVRT) microscope (Applied Precision) using a
Photometrics CoolSNAP HQ camera. Image analysis was
performed using Softworx (Applied Precision). Unless otherwise
indicated, z-stacks with a 0.2 mm z-step size were taken at 60X
magnification. Stacks were subjected to deconvolution analysis
and 2–3 section projections were made superimposing represen-
tative z-planes to generate the final image.
Flow Cytometry
Cells were dissociated with Cellstripper (Cellgro, 25-056-CI)
and resuspended in cold PBS+ containing 2% NGS and 0.1%
sodium azide (NaN3) (Surface Block) for 15 minutes on ice. Cells
were then incubated for 15 minutes on ice with Rabbit anti-HA
antibody diluted 1:100 in cold PBS+ containing 0.2% NGS and
0.1% NaN3 (Surface Wash) followed by 15 minutes on ice with
anti-rabbit Alexa488 secondary antibody at 1:1000 dilution and
1 mM propidium iodide (PI) in 100 ml Surface Wash. Analysis was
on a BD LSR2 flow cytometer. Live, non-necrotic cells were gated
based on scatter characteristics and negative PI staining.
Compensation settings were determined empirically for each
experiment on single color controls using BD CompBeads for
mouse antibodies (552843) and Flow cytometry protein A beads
for rabbit antibodies (Bangs Laboratories 553) and unstained cells
for PI.
CyQuant Proliferation Assay
EC in 96-well plates were infected as above with Trans and
CXCR7 at indicated doses. When applicable, drugs or inhibitors
were added at 6 hours post-infection. At 20 hours post-infection
cells were lysed in buffer containing CyQuant proliferation dye.
Lysates were transferred to white-walled 96-well plates (Costar
3903) and fluorescence was read on a Molecular Devices
Flexstation Plate Reader. All conditions were performed in at
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least 6 biological replicates per experiment. Individual experiments
were normalized to the average of negative control cultures and at
least two experimental replicates were averaged to achieve
statistical power. P-values were generated by Student’s T-test
using Microsoft Excel.
Antibody Microarray
pLEC were infected in duplicate with either Trans only at MOI
100 or Trans MOI 100+ CXCR7 at MOI 50 in EBM-2+ Bullet
Kit Supplements +1% FBS. At 18 hours post-infection cells were
starved in serum free M199 for 1 hour then stimulated for 10
minutes at 37uC with 50 ng/ml rhSDF-1/CXCL12. A subset of
cells were used to verify CXCR7 expression by flow cytometry
(FACS) as described above and duplicate samples were pooled.
Total cellular protein was extracted, biotinylated and hybridized
to PEX100 microarray according to the manufacturer’s instruc-
tions (Full Moon BioSystems, Sunnyvale, CA). Completed slides
were dried and scanned using a ScanArray Lite (Packard
Bioscience) scanner. Optical density of spots and background
subtraction was performed on the scanned images using TotalLab
software. Optical density ratios and sorting were performed in
Microsoft Excel.
Western Blot Analysis
Cells were lysed in 200 ml modified radioimmunoprecipitation
(RIPA) buffer (10 mM Tris pH 7.4, 150 mM NaCl, 1 mM
EDTA, 1%Triton-X-100, 1% Sodium Deoxycholate, 0.1% SDS)
containing protease inhibitors (Roche 11836145001) for 10
minutes on ice. Lysates were freeze-thawed once at 220uC and
protein was quantified by BCA protein assay (Pierce, 23225).
0.5 mg of total lysate was boiled for 5 minutes in 1X LDS protein
sample buffer containing reducing agent (Invitrogen, NP0009),
loaded on NuPAGE 4–12% Bis-Tris gradient protein gels
(Invitrogen, NP0335) and run in 1X NuPAGE MOPS buffer
(Invitrogen, NP0001). Protein was transferred to Immobilon-P
blotting membrane (Millipore, IPVH00010) and membranes were
blocked by drying overnight at RT. Membranes were rehydrated
in 2% ECL advance blocking buffer (Amersham, CPK1075) with
0.2% Tween-20 (Block) for 15 minutes. All subsequent incubations
were performed in Block. Rb primary antibody was at 1:2000
dilution and GAPDH primary antibody was at 1:50,000 dilution 1
hour at RT. HRP-conjugated secondary antibodies were diluted
1:40,000 and incubated for 20 minutes at RT. Blots were
developed using ECL Advance (Amersham, RPN2135) chemilu-
minescent reagent and autoradiography. For all experiments,
adenovirus transduction was verified by analysis of 0.2 mg of
unboiled total protein blotted as above with a direct conjugate
anti-HA-HRP. Densitometry analysis was performed on scanned
western blot results using TotalLab software.
Quantitative RT-PCR Analysis
Extraction of total RNA was performed on cell pellets using
miRNeasy Mini Kit (Qiagen), DNase I treatment (Qiagen) was
employed to degrade DNA from the RNA samples. Total cDNA
was produced by reverse transcribing 200 ng of RNA, using
SuperScript III First-Strand Synthesis System (Invitrogen). The
primers employed for the amplification of the target genes by
qPCR were the following: GAPDHF 59-GAAGGTGAAGGTCG-
GAGT-39, GAPDHR 59-GAAGATGGTGATGGGATTTC-39;
SDF-1 F 59-CTGTCACTGGCGACACGTAG -39, SDF-1 R 59-
TCCCATCCCACAGAGAGAAG-39; CXCR7 F 59-
CTGCGTCCAACAATGAGACCT-39, CXCR7 R 59-CCGAT-
CAGCCACTCCTTGA-39; ITAC-F 59-GTTCAAGGCTTCCC-
CATGTTC-39, ITAC-R 59-CCACTTTCACTGCTTT-
TACCCC-39. To perform the qPCR, 10 ng of cDNA (5 ul of
sample) were loaded on a 96-well optical plate together with 20 ul
of Power SYBR Green PCR Master Mix (ABI) containing the
appropriate set of primers, for a final volume of 25 ul. Evaluation
of primer and sample concentrations has been optimized for all the
targets. Amplification of the samples was performed on Real Time
PCR 7500 System (ABI), according to the manufacturer’s
instructions. Normalized relative gene expression levels were
calculated by applying the DDCT method, which compares the
expression of target genes in treated samples (Adenovirus-infected
cells) to the one in control samples (mock-infected cells). For the
purpose of this quantification, GAPDH was utilized as internal
control and the results were represented as change in the
expression level of each particular gene (fold change).
Quantibody Antibody Array for Supernatant Cytokine
Analysis
pLEC in 3.5 cm dishes were infected as above with Trans at
MOI 200 or Trans+CXCR7 at MOI 100 and incubated for 20
hours at 37uC. At 20 hours post-infection, media was replaced
with 0.5 ml serum free M199 and incubated for 4 hours at 37uC.
After incubation supernatants were frozen in four 250 ml aliquots.
Cells were harvested and analyzed for CXCR7 transduction by
flow cytometry. Duplicate samples were collected from two
independent experiments. Quantibody arrays were stained
according to manufacturers instructions. Briefly, slides were
blocked in sample diluent provided for 30 minutes at RT,
cytokine standard curves were prepared and samples and
standards were hybridized to the array at RT for 2 hours followed
by 5X 5 minute washes. Detection antibody was hybridized to
slides for 2 hours at RT followed by 5X 5 minute washes. Cy3
streptavidin was added for 1 hour at RT, protected from light
followed by 5X 5 minute washes. The array slide was disassembled
and air dried. Scanning and analysis service was performed by
Ray Biotech.
Results
Adenovirus Expression System for CXCR7 in EC
In order to effectively study the ramifications of aberrant
CXCR7 expression in an EC culture system, we constructed a
Tet-inducible CXCR7-expressing adenovirus vector containing
the complete CXCR7 sequence fused to an N-terminal HA-
epitope tag. In this system, we achieve expression of CXCR7 via
co-infection of EC with CXCR7 adenovirus and a second
adenovirus vector expressing the tet-transactivator (hereafter
referred to as Trans). In all experiments, cells transduced with
Trans alone are used to control for nonspecific effects of
adenovirus infection. Indirect immunofluorescence (IFA) analysis
of HA-CXCR7-transduced EC demonstrate comparable staining
with either an HA probe or the CXCR7 monoclonal antibody
11G8 (Figure 1A). Interestingly, this IFA analysis reveals a
punctate intracellular staining pattern consistent with CXCR7
being primarily located in the secretory pathway and endosomes.
In order to determine whether adenovirus-expressed CXCR7 is
also displayed at the cell surface, we performed FACS analysis of
cultures transduced with increasing doses of CXCR7, gating
stringently on intact cells via propidium iodide exclusion. These
experiments revealed that CXCR7 is expressed on the surface of
adenovirus-transduced EC and that surface levels correlate with
adenovirus dose (Figure 1B). We chose to do our experiments in
primary human lymphatic EC (pLEC) because this lineage
displays more robust growth in static culture compared to primary
blood vascular lineage EC (pBEC) and has uniformly low levels of
Aberrant Proliferation of CXCR7+ Endothelial Cells
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baseline CXCR7 expression compared to primary umbilical vein
EC, in which we observe sporadic induction of CXCR7 in single
cells (data not shown). However, we have verified key findings of
the current study in pBEC (Figure S1) in order to verify that these
phenotypes are not specific to the lymphatic lineage.
CXCR7+ EC are Hyperproliferative
In order to determine whether CXCR7 mediates aberrant
proliferation in EC cultures, we generated replication-quiescent
pLEC cultures by growing cells to confluence and maintaining
them at confluence for two days prior to initiating experiments.
Quiescent, contact-inhibited EC were then transduced with
increasing multiplicity of infection (MOI) of Trans only (0, 50,
100 or 200) or Trans at MOI 50 with increasing doses (MOI 0,
100, 200 or 300) of CXCR7 adenovirus. At 20 hours post-
infection wells were lysed in the presence of CyQuant. We
observed that cultures transduced with CXCR7 displayed a dose-
dependent increase in overall cell numbers compared to uninfect-
ed or Trans-only controls. CXCR7-mediated overproliferation
was statistically significant at all doses, while increasing doses of
Trans alone did not result in significantly higher cell numbers
compared to uninfected controls (Figure 1C). Because these
cultures were quiescent prior to transduction, the proliferation
observed in these experiments represents significant, aberrant
post-confluent growth of EC as a result of CXCR7 expression.
Similar results were obtained in pBEC cultures (Figure S1A).
CXCR7+ EC are not Contact Inhibited and Form
Abnormal Monolayers
In order to test whether post-confluent growth is associated with
a loss of contact inhibition in CXCR7+ EC, we infected
subconfluent pLEC with Trans only or Trans+CXCR7. At 20
hours post infection, cells were re-plated into smaller wells so that
cells would form a confluent monolayer without needing to
proliferate further. At 20 hours post-seeding (40 hours post-
infection), wells were fixed and stained for CXCR7 and CD31/
PECAM. Examination of re-plated cultures by deconvolution
microscopy revealed a typical cobblestone monolayer formation
Figure 1. Adenovirus-transduced CXCR7+ EC display dose-dependent overproliferation. (A) pLEC were infected with Trans or
Trans+CXCR7 at MOI 100. At 20 hours post-infection coverslips were fixed and stained for the HA-tag (red), CXCR7 protein via 11G8 monoclonal
antibody (green) and DAPI. Images were taken at 60x magnification. White size bar indicates 30 mm. (B) pLEC were infected with Trans at MOI 50 or
Trans+CXCR7 at indicated doses. At 20 hours post-infection cells were stained live for the HA-tag and analyzed by flow cytometry. Necrotic cells were
excluded from the analysis via propidium iodide staining and scatter characteristics. Positive staining was compared to appropriate isotype control
(grey) and mean fluorescence intensity values were calculated for HA fluorescence (MFI) (C) Confluent pLEC cultures were infected with increasing
doses of Trans only or Trans+increasing doses of CXCR7. At 20 hours post-infection, cells were lysed in the presence of Cyquant. Fluorescence values
are normalized to uninfected controls. n = 24 from three independent experiments. * P=0.01, ** P,0.003.
doi:10.1371/journal.pone.0069828.g001
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with normal junctional CD31 staining in Trans controls. In
contrast, CXCR7-transduced cultures formed highly abnormal
monolayers with areas of multi-layered foci and low or absent
CD31 junctional staining (Figure 2A). Comparing the number of
nuclei per field in 40 random fields revealed that CXCR7+
cultures had significantly higher cell numbers per field, suggesting
that CXCR7+ cultures continue to proliferate even when plated at
confluence (Figure 2B). Taken together, these data reveal that
CXCR7 expression allows EC to grow in a non-contact inhibited
manner.
CXCR7+ EC Display Altered Levels of Critical Proliferation
Mediators
In order to identify potential mechanisms of CXCR7-mediated
proliferation we first sought to determine whether CXCR7
expression affects the expression and/or phosphorylation of
proteins involved in the regulation of cell division. We performed
identical antibody microarrays (Full Moon Systems PEX100) using
lysates from Trans or Trans+CXCR7 infected EC cultures and
compared the two samples to identify proteins specifically altered
in the presence of CXCR7. The complete list of altered expression
and phosphorylation hits is available as supporting documentation
(Table S1). Table 1 shows selected proteins altered by CXCR7
expression that are functionally associated with proliferation.
Importantly, multiple antibody spots demonstrated downregula-
tion of the key tumor suppressor Retinoblastoma protein (Rb) in
CXCR7+ EC.
Retinoblastoma Protein (Rb) Protein is Degraded in
CXCR7+ EC
The pocket protein family member Rb is a critical regulator of
cell cycle progression. Aberrant inhibition of Rb function is a
frequent occurrence in the course of human tumorigenesis [20].
Consistent with our microarray data, western blot analysis of
lysates from pLEC cultures revealed a dose-dependent degrada-
tion of total Rb protein in CXCR7-expressing EC compared to
Trans controls (Figure 3A). Densitometry analysis of nine sample
sets from six independent experiments performed with CXCR7-
transduction at an MOI of 200 revealed that this phenotype is
reproducible with an average 2.860.3 fold decrease of total Rb
protein in CXCR7+ cultures compared to Trans controls. Similar
Rb degradation was observed in CXCR7-transduced pBEC
(Figure S1B). Others have shown that Rb degradation can occur
in cancer cells via a proteasome-mediated mechanism [21]. In
order to test whether the proteasome is responsible for CXCR7-
mediated Rb degradation, we performed similar experiments in
which DMSO vehicle or the proteasome inhibitor MG132 was
added to transduced cultures at 6 hours post-infection. Indeed, Rb
expression is restored in CXCR7+ EC treated with MG132,
demonstrating that Rb degradation in this system is mediated by
the proteasome (Figure 3B). Taken together, these results
demonstrate that CXCR7 expression in EC results in the
proteasomal degradation of the tumor suppressor protein Rb,
providing a potential mechanism for the aberrant proliferation
seen in CXCR7+ EC cultures.
Expression of CXCR7 Ligands and EC Growth Factors are
not Significantly Altered in CXCR7+ EC
We next wanted to determine whether expression of the known
CXCR7 chemokine ligands SDF-1/CXCL12 and ITAC/
CXCL11 is altered in CXCR7-transduced EC cultures. In these
experiments we transduced pLEC with increasing doses of
CXCR7 adenovirus, harvested cells at 20 hours post-infection
and performed quantitative RT-PCR analysis for mRNA expres-
sion of CXCR7, SDF-1/CXCL12 and ITAC/CXCL11 (Table 2).
These results reveal that CXCR7 expression has no effect on
expression of SDF-1/CXCL12 transcripts. We observed a small
reproducible induction of ITAC/CXCL11 at higher doses of
CXCR7. We wanted to confirm these results by determining the
concentration of CXCR7 ligands in EC culture supernatants.
Additionally, we wanted to rule out the possibility that the
proliferation of CXCR7+ EC cultures was a result of indirect
induction of secreted growth factors. For these experiments, we
harvested supernatants at 20 hours post-infection from duplicate
experiments in which pLEC were transduced with Trans or
Trans+CXCR7. Cytokine levels in the supernatants were analyzed
using a custom QuantibodyH antibody array (Ray Biotech). We
found that transduction of EC with CXCR7 does not significantly
or reproducibly alter supernatant levels of any of the cytokines
assayed (Table 3). We did detect low levels of ITAC/CXCL11 in
some samples, consistent with our RT-PCR results. Although we
were unable to detect SDF-1/CXCL12 in the culture superna-
tants, SDF-1/CXCL12 is known to be highly cell-associated
through glycosaminoglycan interactions [22] and, as such, we
cannot rule out the presence of SDF-1/CXCL12 in these cultures.
CXCR7-mediated Rb Degradation is Ligand-dependent
but not Ligand-specific
In order to determine whether Rb degradation in CXCR7+ EC
is mediated by CXCR7 ligands, we performed experiments in
which transduced pLEC cultures were treated with increasing
doses of neutralizing antibodies directed against the two CXCR7
ligands SDF-1/CXCL12 or ITAC/CXCL11. Western blot
analysis of cellular lysates revealed a dose-dependent rescue of
Rb expression with neutralization of either SDF-1/CXCL12
(Figure 4A) or ITAC/CXCL11 (Figure 4B). The finding that
SDF-1/CXCL12 neutralizing antibody abrogates CXCR7-medi-
ated Rb degradation suggests that there is cell-associated SDF-1/
Figure 2. CXCR7+ EC are not contact inhibited. (A) pLEC were
infected with Trans only or Trans+CXCR7. At 20 hours post-infection
cells were trypsinized, counted and replated onto chamber slides at
confluence and allowed to attach for a further 20 hours. Resulting
monolayers were fixed and stained for DAPI (blue), CD31 (green), and
CXCR7 (red). (B) Nuclei were counted in 10 random fields from 2
independent wells from 2 independent experiments (n = 40, P,0.0001).
doi:10.1371/journal.pone.0069828.g002
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CXCL12 present in pLEC cultures that was not detected in the
supernatant. These results demonstrate that CXCR7-mediated Rb
degradation requires CXCR7 ligand. Importantly, this phenotype
is not ligand-specific because rescue of Rb can be achieved by
neutralization of either CXCR7 ligand.
CXCR7 Transduction does not Affect Surface Expression
of CXCR3 and CXCR4
CXCR7 shares ligands with two other chemokine receptors;
SDF-1/CXCL12 binds to both CXCR7 and CXCR4 while
ITAC/CXCL11 binds to both CXCR7 and CXCR3 [9]. Indeed,
it has been hypothesized that CXCR7 is not a functional
chemokine receptor but a chemokine sink and that its primary
function is to alter the availability of ligands for these alternate
receptors [11,23,24]. This promiscuity makes receptor/ligand
interactions difficult to dissect in EC, which can express both
CXCR4 and CXCR3 [4,25]. Therefore, we wanted to rule out
participation of these alternate receptors in the ligand-dependent
degradation of Rb seen in CXCR7+ cultures. We performed
experiments in which we transduced pLEC with increasing
concentrations of CXCR7 adenovirus and detected surface
expression of CXCR7, CXCR3 and CXCR4 by flow cytometry
(Figure 5). We observed dose-dependent increases in CXCR7
expression as expected. However, we observed no CXCR4
staining above isotype control in any condition and although a
small number of CXCR3 positive EC were observed in these
experiments (4% 60.8 average from 8 samples in two experi-
mental replicates), CXCR7 transduction did not alter CXCR3
levels. These results demonstrate that cell surface expression of
alternate receptors for CXCR7 ligands in pLEC cultures is very
Table 1. Selected proliferation-related proteins displaying modified expression or phosphorylation in CXCR7+ EC.
Protein Name (antibody/phosphorylation site) Expression Level (CXCR7/Trans)
GSK3a-b (Ab-216/279) 6.3
DAXX (Phospho-Ser668) 3.4
EGFR (Ab-1069) 2.2
p53 (Phospho-Thr81) 0.5
Stathmin 1(Ab-15) 0.5
p53 (Ab-18) 0.4
p53 (Ab-378) 0.4
Rb (Ab-780) 0.4
Rb (Ab-780) 0.4
Cyclin D3 (Ab-283) 0.4
Cyclin E1 (Phospho-Thr77)) 0.4
Stathmin 1(Ab-37) 0.4
Rac1/cdc42 (Ab-71) 0.3
doi:10.1371/journal.pone.0069828.t001
Figure 3. CXCR7 expression causes degradation of Rb in EC. (A)
pLEC cultures were infected with Trans only (0) or Trans+CXCR7 at MOI
50, 100 or 200. At 20 hours post-infection, cells were lysed and analyzed
by western blot for total Rb levels. Densitometry analysis was
performed on Rb blots wherein each sample was normalized to GAPDH
signal intensity and GAPDH-normalized fold decrease of Rb expression
compared Trans is displayed beneath each dose (B) pLEC cultures were
infected with Trans only or Trans+CXCR7. At 6 hours post-infection,
media was replaced with media containing DMSO vehicle or media
containing MG132 at 1 or 2.5 mM. At 20 hours post infection, cells were
lysed and analyzed by western blot for total Rb levels.
doi:10.1371/journal.pone.0069828.g003
Table 2. Fold changes in mRNA expression in CXCR7-
transduced EC compared to uninfected controls.
CXCR7 SDF-1/CXCL12 ITAC/CXCL11
Trans 0.260.1 1.260.6 1.060.3
CXCR7 MOI 50 150.1619.9 0.860.4 1.060
CXCR7 MOI 100 578.9635 0.960.5 2.560.8
CXCR7 MOI 200 1114.96117.4 1.060.5 2.860.1
Average 6 standard error of two experimental replicates.
doi:10.1371/journal.pone.0069828.t002
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low and is not affected by CXCR7 expression. Therefore, it is
unlikely that the significant gain-of-function proliferation and Rb
degradation phenotypes seen in CXCR7-transduced cultures is a
result of signaling from these alternate receptors.
Pharmacological Inhibition of CXCR7 Restores Rb
Expression and Prevents Overconfluent Growth
In order to reinforce our hypothesis that CXCR7-mediated EC
proliferation and Rb degradation is a result of CXCR7 signaling,
we examined the effect of a small molecule inhibitor of CXCR7,
CCX733, on proliferation and Rb protein levels in CXCR7+ EC.
For these experiments, we transduced confluent pLEC cultures
with Trans or Trans+CXCR7. At 6 hours post-infection, we
added DMSO vehicle or increasing doses (10, 50 or 100 nM) of
CCX733. While the inhibitor was ineffective at 10 nM, treatment
with 50 nM CCX733 produced a statistically significant decrease
in the overproliferation seen in CXCR7+ EC cultures. The effect
was more pronounced at 100 nM, however we observed a low
level of cytotoxicity at this dose indicated by a decrease in cell
numbers in the control Trans cultures (Figure 6A). Similar
experiments in which we harvested total cellular lysates and
performed western blot analysis for Rb protein levels revealed a
partial rescue of Rb levels in cultures treated with CCX733
(Figure 6B). Therefore, pharmacological inhibition of CXCR7 can
prevent aberrant proliferation and Rb degradation in EC.
Moreover, these results show a direct correlation between Rb
levels and proliferative capacity in CXCR7+ EC.
Expression of a CXCR7 Mutant Rescues Rb and Displays
Lower Proliferation Levels
The N-terminal domain mediates high affinity chemokine
interaction for both CXC [26] and CC [27] chemokine receptors.
Therefore, we deleted five N-terminal amino acids from the
CXCR7 sequence in our existing CXCR7 adenovirus vector
(CXCR7-D5). The N-terminal HA-tag was retained to aid in
detection. Flow cytometry analysis of pLEC transduced with
CXCR7-D5 demonstrated that the modified protein is expressed
on the cell surface (Figure 7A). In contrast to wild-type (WT)
CXCR7 transduction, lysates from CXCR7-D5-transduced cul-
tures displayed no degradation of Rb protein by western blot
analysis (Figure 7B). Moreover, CyQuant analysis of confluent
pLEC cultures transduced with increasing levels of CXCR7-D5
display decreased proliferation compared to CXCR7-WT
(Figure 7C). Taken together, these results indicate that the
proliferation phenotype associated with CXCR7-expression in
EC can be abrogated by expression of a CXCR7 mutant,
supporting our hypothesis that these phenotypes require interac-
tion between CXCR7 and its chemokine ligands and further
demonstrating that the degradation of Rb corresponds to
proliferative capacity in these cultures.
Discussion
Since its identification as an alternate SDF-1/CXCL12 binding
receptor, CXCR7 has been the subject of intense study in the
cancer field. However, dissection of CXCR7 signaling and
function has proven difficult for several reasons. First and most
importantly, the promiscuity of CXCR7 ligands and the
widespread expression of CXCR4 and CXCR3 in tumor tissues
[6] makes the dissection of CXCR7-specific signaling particularly
Table 3. Supernatant concentrations of selected cytokines in
Trans or CXCR7-transduced EC.
Experiment 1 Experiment 2
Trans CXCR7 Trans CXCR7 LOD MAX
SDF-1/CXCL12 0.0 0.0 0.0 0.0 10.0 60,017
I-TAC/CXCL11 0.0 89.0 77.0 0.0 54.0 60,012
6ckine/CCL21 0.0 0.0 241.0 0.0 183.0 60,000
ANG-1 0.0 0.0 0.0 0.0 36.0 60,002
ANG-2 381471.0 465732.0 1447429.0 1162435.0138.0 60,003
EGF 786496.0 820226.0 9955.0 9158.0 158.0 60,005
ENA-78/CXCL5 180.0 212.0 0.0 0.0 110.0 60,006
HGF/SF 301.0 0.0 502.0 0.0 199.0 60,008
IL-8/CXCL8 310714.0 374540.0 146329.0 125787.0 137.0 60,009
IP-10/CXCL10 0.0 0.0 0.0 0.0 28.0 60,011
MIG/CXCL9 644.0 790.0 3569.0 1844.0 282.0 60,014
MIP-3b/CCL19 0.0 0.0 0.0 0.0 28.0 60,015
VEGF 0.0 141.0 0.0 0.0 119.0 60,018
VEGF-C 0.0 0.0 0.0 0.0 81.0 60,020
VEGF-D 0.0 0.0 0.0 0.0 37.0 60,021
Quantities are displayed in pg/ml.
LOD: Limit of Detection; MAX: maximum concentration of standard curve.
ANG: angiopoietin; EGF: epidermal growth factor; HGF/SF: hepatocyte growth
factor/scatter factor; VEGF: vascular endothelial growth factor.
doi:10.1371/journal.pone.0069828.t003
Figure 4. CXCR7-mediated Rb degradation requires ligand.
pLEC cultures were infected with Trans only or Trans+CXCR7. At 6 hours
post-infection, media was replaced with media only or media
containing (A) SDF-1/CXCL12 neutralizing antibody at 1.5, or 3.0 mg/
ml or (B) ITAC/CXCL11 neutralizing antibody at 0.5 or 1.0 mg/ml. At 20
hours post infection, cells were lysed and analyzed by western blot for
total Rb levels. Densitometry analysis was performed and fold change
values were calculated from GAPDH-normalized optical density ratios as
described for Figure 3. Bar graphs (bottom) represent the average fold
change at each condition for two independent experiments.
doi:10.1371/journal.pone.0069828.g004
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challenging. Moreover, tumor cells can produce both SDF-1/
CXCL12 [5] and ITAC/CXCL11 [28,29], creating a complex
signaling background and making experiments with exogenous
chemokine ligand difficult to interpret. Third, it is clear from the
current lack of consensus in the CXCR7 literature that CXCR7
signaling is likely to be both cell-type specific and ligand-specific, a
phenomenon that has been described for other G-protein coupled
receptors (GPCRs) [30] and chemokine receptors [31]. The latter
challenge, in particular, necessitates careful examination of
CXCR7 function in the cell type of interest, because the biological
effects of CXCR7 expression and signaling are not necessarily
universal between tissue types.
To our knowledge, all of the studies examining CXCR7
expression in tumor vasculature have used CD31/PECAM-1 as a
marker of EC. As such, the vessels represented could be blood
vascular, lymphatics or, most likely, both. Although we have
performed the majority of experiments in the current study using
primary lymphatic EC, we have shown that aberrant proliferation
and Rb degradation occurs in blood vascular lineage EC as well
(Figure S1). As such, the physiological implications of the current
study are generalizable to both the lymphatic and blood vascular
circulatory systems. The importance of tumor lymphatic vascula-
ture to tumor immune surveillance [32] as well as the metastatic
spread of tumors to the lymph nodes [33,34] is well established.
Figure 5. CXCR7 transduction does not affect surface expression of CXCR3 and CXCR4. pLEC cultures were infected with Trans only or
Trans+CXCR7 at indicated doses. At 20 hours post-infection cells were harvested and stained by flow cytometry for CXCR7 via 8F11 monoclonal
antibody, CXCR4 and CXCR3. Necrotic cells were excluded from the analysis via propidium iodide staining and scatter characteristics. Positive staining
(black line) was compared to appropriate isotype control (grey fill) and positive populations were gated based on isotype control levels. Data is
representative of two experimental replicates.
doi:10.1371/journal.pone.0069828.g005
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We believe that our current data supports further study into the
contribution of CXCR7 expression in tumor-associated lymphatic
vessels to tumor growth and metastasis.
Pathologically-induced CXCR7 has recently been shown to
drive proliferation of pulmonary microvascular EC in models of
pulmonary hypertension in vitro [35] and in vivo [19]. Moreover,
the latter study demonstrated that pharmacological inhibition of
CXCR7 could prevent vascular proliferation caused by chronic
hypoxia-induced pulmonary hypertension. While these results are
not necessarily translatable to tumor vascular dysfunction we
believe that, when taken together with our current study in
primary human EC and the wealth of histopathological data
showing that CXCR7 is highly expressed in tumor vasculature, the
potential of CXCR7 as an antiangiogenic target deserves further
study.
Figure 6. A small molecule inhibitor of CXCR7 prevents
overconfluent growth and restores Rb expression. (A) Confluent
pLEC cultures were infected with Trans only or Trans+CXCR7. At 6 hours
post-infection, media was replaced with media containing DMSO
vehicle control or CCX733 at 10 nM, 50 nM or 100 nM. At 20 hours
post-infection, cells were lysed in the presence of Cyquant. Floures-
cence values are normalized to Trans+DMSO control. n.10 from two
independent experiments. **P,0.01 (B) pLEC cultures were infected
and treated as described for (A). At 20 hours post-infection, cells were
lysed and analyzed by western blot for total Rb levels. Densitometry
analysis was performed and fold change values were calculated from
GAPDH-normalized optical density ratios as described for Figure 3.
doi:10.1371/journal.pone.0069828.g006
Figure 7. Expression of a CXCR7 mutant rescues Rb and
prevents aberrant proliferation. (A) pLEC cultures were transduced
with CXCR7 WT at MOI 200 or CXCR7-D5 at MOI 50. At 20 hours post-
infection cells were stained for surface expression of the HA tag.
Propidium Iodide was used to exclude necrotic cells. (B) Total lysates
from pLEC cultures transduced as in (A) were harvested and analyzed by
western blot analysis for total Rb protein. (C) Confluent pLEC cultures
transduced with increasing doses of CXCR7-WT (MOI 50, 100, 200 or
300) or CXCR7-D5 (MOI 10, 20, 30 or 50). At 20 hours post-infection, cells
were lysed in the presence of Cyquant. Fluorescence values are
normalized to Trans only controls. n = 10. * P= 0.03, ** P= 0.001.
doi:10.1371/journal.pone.0069828.g007
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When CXCR7 was still the orphan GPCR known as RDC1,
our laboratory demonstrated that CXCR7 is highly upregulated in
EC infected with Kaposi Sarcoma Herpesvirus (KSHV) [36].
KSHV is the etiological agent of Kaposi Sarcoma (KS) an
angioproliferative tumor of the viscera, skin and mucosa in which
the tumor cell is of endothelial origin [37]. Importantly, in our
original study, knockdown of CXCR7 by RNA interference
abrogated the ability of KSHV to produce a transformed
phenotype in EC cultures, providing the first evidence that
aberrant expression of CXCR7 contributes to malignancy. To our
knowledge, KS is the only neoplasm studied to date that displays
uniformly high levels of CXCR7 on tumor cells, and we have
observed that levels of CXCR7 expression correlate with disease
progression (Moses et. al, unpublished observations). Results from
our current study provide CXCR7-mediated proliferation as a
potential mechanism for the growth of KS tumors and establish
CXCR7 as a potential target for the treatment of KS. Indeed, the
expression of CXCR7 in other angioproliferative neoplasms will
be of great interest in future studies.
There is significant evidence in the literature that CXCR7 alters
the function of CXCR4 either by direct interaction or manipu-
lation of ligand availability [23,24,38]. Experiments employing
CXCR4 inhibitors would further strengthen the conclusion that
CXCR4 is not involved in the observed phenotypes. Unfortu-
nately, two CXCR4 antagonists AMD3100 and TC14012 are
known agonists for CXCR7 [39,40] and, to our knowledge, the
other CXCR4 antagonists have not been tested for CXCR7
binding capacity. Therefore, we believe that the use of CXCR4
inhibitors would be uninterpretable in our EC system. We have
demonstrated that surface expression of both CXCR3 and
CXCR4 are very low in these cultures and are not altered by
CXCR7 expression (Figure 5), and we have utilized both a small
molecule inhibitor of CXCR7 and targeted mutagenesis of the
CXCR7 N-terminus to abrogate the observed phenotypes
(Figures 6 & 7). We believe that, taken together, the data
presented in the current study supports the conclusion that the
proliferative phenotypes observed in CXCR7+ EC are a direct
result of CXCR7 signaling and represent the most rigorous
demonstration thereof that is possible given the complexity of the
system and the tools currently available.
In the current study, we demonstrate that CXCR7 expression
causes the proteasome-mediated degradation of Rb protein in EC,
providing a specific cellular mechanism for CXCR7-mediated
proliferation. To our knowledge, this is the first demonstration of
CXCR7-mediated inhibition of a tumor suppressor pathway. The
Rb regulatory pathway is thought to be dysfunctional in most
human cancer [20]. Indeed, the function of Rb as a master
regulator of cellular proliferation was first appreciated when it was
shown to be the target of several viral oncogenes. Virus-mediated
inhibition of Rb function proceeds by a variety of mechanisms
including (1) direct phosphorylation of Rb, (2) steric inhibition of
Rb interactions with the E2F transcription factor and (3) targeting
of Rb protein for degradation [41,42]. These virus-mediated
oncogenic mechanisms provide clues to potential cellular mech-
anisms of Rb inactivation in uninfected malignant cells, some of
which have since been revealed. Overexpression of the E3
ubiquitin ligase MDM2 is one of the only cellular mechanisms
for degradation of Rb in cancer cells that has been characterized
to date [21], but the factors driving MDM2 overexpression in
cancer systems remain obscure. It will be interesting to determine
whether aberrant expression of CXCR7 in EC results in
overexpression or activation of MDM2 and whether MDM2
affects Rb expression in EC. Moreover, if the phenotype we
demonstrate is common and CXCR7 signaling causes degradation
of Rb in tumor cells in other cancer systems, the inhibition of
CXCR7 could be a powerful target for the treatment of malignant
cellular proliferation in general.
Although we have chosen to focus on Rb as a protein of interest
from our antibody microarray screen of CXCR7-modulated
proteins, we provide the complete list of proteins and phosphor-
ylation sites found to be modified by CXCR7 expression as
supporting information (Table S1). In addition to identifying
additional proliferation-modulators affected by CXCR7 - includ-
ing, notably, the tumor suppressor protein p53 (Table 1) – these
data also suggest that CXCR7 may participate in the control of
apoptosis and participate in the response of EC to environmental
stress. We anticipate that this data set will help further the studies
of researchers in multiple fields related to EC biology and CXCR7
signaling.
Supporting Information
Figure S1 CXCR7 expression in pBEC results in post-
confluent proliferation and causes Rb degradation.
Confluent pBEC cultures were infected with Trans only or
Trans+CXCR7 at MOI 100. At 20 hours post-infection cells were
(A) lysed in the presence of CyQuant or (B) lysed and analyzed by
western blot for total Rb levels. Fluorescence values are
normalized to uninfected controls. n = 18 from three independent
experiments. *** P,0.001.
(PDF)
Table S1
(PDF)
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